Fig. 1

Design of the MiroCIP study, which comprised a registrational study and an interventional study. Same-type cancer patients with chemotherapy-induced peripheral neuropathy (CIPN) and receiving oxaliplatin or taxanes outside the registration study part did not participate in the 1-year follow-up registration part of the MiroCIP study. CTCAE, Common Terminology Criteria for Adverse Events; NSCL, non-small-cell lung